Breaking the ground for WuXi STA’s new pharmaceutical facility in Delaware
WuXi AppTec subsidiary and leading CRDMO, WuXi STA, has broken the ground at the site for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.
WuXi STA, a subsidiary of WuXi AppTec based in Shanghai, China, have broken the ground for their latest 190-acre pharmaceutical manufacturing campus in Middletown Delaware. The project was announced in June 2021 and promises WuXi STA’s second facility in the United States to offer expanded capacity and greater flexibility for their customers.
The new, state-of-the-art facility will offer approximately 500 full-time jobs by 2026, and provide a site for formulation development, clinical and commercial drug product manufacturing services in addition to packaging, labelling and storage and distribution for clinical trial and commercial drug materials and products. With 12 sites across the United States, Europe, and Asia, WuXi STA hopes to continue offering their services across the globe.
WuXi STA specializes in pharmaceutical development and manufacturing capabilities, offering solutions for integrated chemical, manufacturing, and controls as a premier CRDMO. Parent company WuXi AppTec operates with a global portfolio of research and development and manufacturing services for the pharmaceutical and healthcare industries to advance discoveries and manufacturing, delivering essential therapies to patients.
Delaware Governor John Carney commented: “The biopharmaceutical industry is part of Delaware’s DNA… Over the next 5 years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth.”
Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, added: “I would like to thank our federal, state, and local partners in Delaware for their continued support in the establishment of this site… WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated contract research, development, and manufacturing organization platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.
Source: WuXi STA (stapharma.com)
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...